Erin Kelly, from Queensland, Australia, recently learned she had the disease after inheriting a rare genetic mutation called ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Koenraad Köllmann is bicycling from Portland, Oregon to Portland, Maine, in a powerful message to end the stigma.

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Biogen’s new product launches were a major highlight, generating $252 million in revenue. This marked a 26% increase quarter-over-quarter and a 91% increase year-over-year, effectively offsetting ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.